NeoPUTTY & REG; Versus NeoMTA 2 & REG; as a Pulpotomy Medicament for Primary Molars: A Randomized Clinical Trial

Purpose: The purpose of this randomized clinical trial was to evaluate the clinical and radiographic success of the premixed bioceramic (NeoPUTTY (R)) as pulpotomy medicament in primary molars in comparison to NeoMTA (R) 2. Methods: Seventy primary molars indicated for pulpotomy in 42 children were randomly allocated into two groups: (1) a mineral trioxide aggregate (MTA) group (NeoMTA (R) 2); and (2) a premixed bioceramic group (NeoPUTTY (R)). Clinical and radiographic examinations of the molars following pulpotomy were conducted by two independent evaluators at six and 12 months. The data were analyzed using Fisher's exact tests. Results: At 12 months, the clinical and radiographic success for the MTA group were 100 percent (34 out of 34) and 94.1 percent (32 out of 34), respectively. For the NeoPUTTY (R) group, the clinical and radiographic success were 97.1 percent (34 out of 35) and 92.8 percent (32 out of 35), respectively. No significant differences were found between the two materials. Conclusions: NeoPUTTY (R) showed a comparable success to mineral trioxide aggregate in primary molar pulpotomies over 12 months. Further clinical trials with larger sample sizes and longer follow-up periods are recommended.